BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 21348536)

  • 21. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
    Iino Y; Takahashi E; Ida S; Kikuchi S
    Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
    Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
    Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.
    Stein ML; Villanueva JM; Buckmeier BK; Yamada Y; Filipovich AH; Assa'ad AH; Rothenberg ME
    J Allergy Clin Immunol; 2008 Jun; 121(6):1473-83, 1483.e1-4. PubMed ID: 18410960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
    Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
    Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mepolizumab for eosinophilic severe asthma: recent studies.
    Robinson DS; Kariyawasam HH
    Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mepolizumab in the treatment of severe eosinophilic asthma.
    Fainardi V; Pisi G; Chetta A
    Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study.
    Sabogal Piñeros YS; Bal SM; van de Pol MA; Dierdorp BS; Dekker T; Dijkhuis A; Brinkman P; van der Sluijs KF; Zwinderman AH; Majoor CJ; Bonta PI; Ravanetti L; Sterk PJ; Lutter R
    Am J Respir Crit Care Med; 2019 Feb; 199(4):508-517. PubMed ID: 30192638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
    Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
    Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
    Nagase H; Ueki S; Fujieda S
    Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
    Busse WW; Ring J; Huss-Marp J; Kahn JE
    J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
    Corren J
    Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
    Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
    J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
    J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mepolizumab-based therapy in asthma: an update.
    Walsh GM
    Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):392-6. PubMed ID: 26110690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current update on eosinophilic lung diseases and anti-IL-5 treatment.
    Samitas K; Rådinger M; Bossios A
    Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):189-205. PubMed ID: 21824072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.
    Gupta A; Pouliquen I; Austin D; Price RG; Kempsford R; Steinfeld J; Bradford ES; Yancey SW
    Pediatr Pulmonol; 2019 Dec; 54(12):1957-1967. PubMed ID: 31502421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
    Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
    Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma.
    Busse WW; Katial R; Gossage D; Sari S; Wang B; Kolbeck R; Coyle AJ; Koike M; Spitalny GL; Kiener PA; Geba GP; Molfino NA
    J Allergy Clin Immunol; 2010 Jun; 125(6):1237-1244.e2. PubMed ID: 20513521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.